Periventricular Nodular Heterotopia

Genetic MONDO:0010233 Pathograph 3 Neuronal Migration Disorder Malformation of Cortical Development

Periventricular nodular heterotopia (PVNH) is a neuronal migration disorder characterized by nodules of gray matter lining the lateral ventricles due to failure of neurons to migrate from the ventricular zone to the cortex during embryonic development. The X-linked dominant form, caused by loss-of-function variants in FLNA (filamin A), predominantly affects females, as hemizygous males typically die in utero. Clinical features include epilepsy (often the presenting symptom), normal to borderline intelligence, cardiovascular anomalies (patent ductus arteriosus, progressive valvular dystrophy, aortic dissection), chronic obstructive lung disease, gastrointestinal dysmotility, coagulopathy, and joint hypermobility. Seizures typically begin at variable age of onset and may be difficult to treat. A concerning median diagnostic latency of 17 to 20 years between seizure onset and genetic diagnosis has been reported.

Ask OpenScientist

Ask a research question about Periventricular Nodular Heterotopia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
4
Pathophys.
9
Phenotypes
3
Pathograph
1
Genes
4
Treatments
1
References
1
Deep Research
👪

Inheritance

1
X-linked Dominant HP:0001423
X-linked dominant inheritance
⚙

Pathophysiology

4
FLNA Loss of Function and Neuronal Migration Failure
Filamin A (FLNA) is a large actin-cross-linking phosphoprotein that transduces ligand-receptor binding into actin reorganization and is required for locomotion of many cell types. In the developing cerebral cortex, FLNA shows high-level expression and is required for neuronal migration from the ventricular zone to the cortical plate. Loss-of-function variants in FLNA disrupt actin cytoskeletal dynamics, preventing neurons from migrating to the cortex. These neurons persist as nodules lining the ventricular surface.
Neuron link Radial glial cell link
FLNA link
Neuronal migration link Actin cytoskeleton organization link Cell-matrix adhesion link
actin filament binding link
Cerebral cortex link Lateral ventricle link
Downstream
Epileptogenesis from Heterotopic Nodules
Show evidence (3 references)
PMID:9883725 SUPPORT Human Clinical
"In the X-linked dominant human disorder periventricular heterotopia (PH), many neurons fail to migrate and persist as nodules lining the ventricular surface."
The landmark paper identifying FLNA (then FLN1) as the causative gene for X-linked periventricular heterotopia, demonstrating its role in neuronal migration.
PMID:9883725 SUPPORT Human Clinical
"We have identified the PH gene as filamin 1 (FLN1), which encodes an actin-cross-linking phosphoprotein that transduces ligand-receptor binding into actin reorganization, and which is required for locomotion of many cell types."
Establishes FLNA as an actin-binding protein required for cell locomotion, explaining the neuronal migration failure mechanism.
PMID:14988809 SUPPORT Human Clinical
"Two disorders, periventricular nodular heterotopia (PVNH) and a group of skeletal dysplasias belonging to the oto-palato-digital (OPD) spectrum, are caused by FLNA mutations. They are considered mutually exclusive because of the different presumed effects of the respective FLNA gene mutations,..."
Zenker et al. 2004 describes a patient with dual PVNH and FMD phenotype from a single FLNA mutation producing both loss-of-function and gain-of-function transcripts, reinforcing the mechanistic distinction between PVNH (loss-of-function) and OPD (gain-of-function).
Epileptogenesis from Heterotopic Nodules
The ectopic gray matter nodules lining the ventricles form abnormal neuronal circuits that are intrinsically epileptogenic, generating seizures due to aberrant synaptic connectivity and network organization. Most affected females initially present with difficult to treat seizures at variable age of onset.
Neuron link
Synaptic transmission link
Lateral ventricle link
Show evidence (1 reference)
PMID:26471271 SUPPORT Human Clinical
"Most affected females are reported to initially present with difficult to treat seizures at variable age of onset."
Large cohort study of 47 FLNA-PVNH patients confirming seizures as the most common presenting symptom.
Cardiovascular Connective Tissue Dysfunction
FLNA is widely expressed in cardiovascular tissues where it plays a role in vascular integrity and cardiac valve development. Loss of FLNA function leads to cardiovascular abnormalities including patent ductus arteriosus, progressive dystrophic cardiac valve disease, and aortic dissection. Severe ascending aortic dilation with aortic regurgitation has been observed in patients even after lung transplantation.
Endothelial cell link Smooth muscle cell link
Heart valve development link Vascular development link
Heart link Aorta link
Show evidence (2 references)
PMID:9883725 SUPPORT Human Clinical
"Females with PH present with epilepsy and other signs, including patent ductus arteriosus and coagulopathy"
Original description establishing cardiovascular involvement (PDA) as part of the FLNA-PVNH phenotype.
PMID:28457522 SUPPORT Human Clinical
"in all patients, severe ascending aortic dilation has been observed with aortic regurgitation"
Documents progressive aortic dilation in FLNA-PVNH patients who underwent lung transplantation, highlighting cardiovascular complications.
Progressive Lung Disease
A recently recognized phenotypic consequence of loss-of-function FLNA mutations is childhood-onset interstitial and obstructive lung disease. Infants may present with progressive respiratory failure requiring escalating ventilator support, pulmonary arterial hypertension, and in severe cases, lung transplantation. Rare surviving males with residual protein function can present with severe lung disease.
Pulmonary alveolar type 2 cell link
Lung development link
Lung link
Show evidence (2 references)
PMID:28457522 SUPPORT Human Clinical
"Respiratory failure secondary to progressive obstructive lung disease during infancy may be the presenting phenotype of FLNA-associated periventricular nodular heterotopia."
Describes a cohort of 6 female infants with FLNA loss-of-function who presented with progressive respiratory failure requiring lung transplantation.
PMID:30547349 SUPPORT Human Clinical
"The respiratory phenotype in the form of childhood interstitial lung disease is a recently recognised clinical consequence of loss-of-function FLNA mutation."
Review confirming interstitial lung disease as an emerging phenotype of FLNA loss-of-function mutations.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Periventricular Nodular Heterotopia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

9
Blood 1
Coagulopathy Occasional Abnormal bleeding (HP:0001892)
Show evidence (2 references)
PMID:9883725 SUPPORT Human Clinical
"Females with PH present with epilepsy and other signs, including patent ductus arteriosus and coagulopathy"
Coagulopathy identified in the original FLNA-PVNH gene discovery.
PMID:20301392 SUPPORT Human Clinical
"macrothrombocytopenia"
GeneReviews confirms macrothrombocytopenia as part of FLNA deficiency.
Cardiovascular 2
Patent Ductus Arteriosus Frequent Patent ductus arteriosus (HP:0001643)
Show evidence (2 references)
PMID:9883725 SUPPORT Human Clinical
"Females with PH present with epilepsy and other signs, including patent ductus arteriosus and coagulopathy"
Patent ductus arteriosus identified as part of the PVNH phenotype in the original gene discovery paper.
PMID:20301392 SUPPORT Human Clinical
"congenital heart disease (patent ductus arteriosus, atrial and ventricular septal defects), valvular dystrophy"
GeneReviews confirms PDA and other cardiac defects as part of the FLNA deficiency spectrum.
Progressive Valvular Dystrophy and Aortic Dilation Occasional Aortic aneurysm (HP:0004942)
Show evidence (2 references)
PMID:26471271 SUPPORT Human Clinical
"Distinct associated extracerebral findings have been observed and may help to establish the diagnosis including patent ductus arteriosus Botalli, progressive dystrophic cardiac valve disease and aortic dissection"
Large cohort confirms progressive cardiovascular complications including valvular dystrophy and aortic dissection.
PMID:28457522 SUPPORT Human Clinical
"in all patients, severe ascending aortic dilation has been observed with aortic regurgitation"
Progressive aortic dilation observed even after lung transplant, highlighting ongoing cardiovascular risk.
Digestive 1
Gastrointestinal Dysmotility Occasional Chronic constipation (HP:0012450)
Show evidence (2 references)
PMID:26471271 SUPPORT Human Clinical
"chronic constipation"
Large PVNH cohort identifies chronic constipation as an associated feature.
PMID:20301392 SUPPORT Human Clinical
"gastrointestinal dysmotility and obstruction"
GeneReviews confirms GI dysmotility as part of FLNA deficiency.
Musculoskeletal 1
Joint Hypermobility Frequent Joint hypermobility (HP:0001382)
Show evidence (1 reference)
PMID:20301392 SUPPORT Human Clinical
"joint hypermobility"
GeneReviews lists joint hypermobility as part of FLNA deficiency spectrum.
Nervous System 3
Epilepsy Very frequent Seizure (HP:0001250)
Show evidence (2 references)
PMID:26471271 SUPPORT Human Clinical
"Most affected females are reported to initially present with difficult to treat seizures at variable age of onset."
Large cohort confirming seizures as the predominant presenting feature in FLNA-PVNH.
PMID:26471271 SUPPORT Human Clinical
"a concerning median diagnostic latency of 17 to 20 years was noted between seizure onset and the genetic diagnosis"
Highlights the significant delay between symptom onset and molecular diagnosis.
Periventricular Nodular Heterotopia Very frequent Periventricular nodular heterotopia (HP:0032388)
Show evidence (1 reference)
PMID:9883725 SUPPORT Human Clinical
"many neurons fail to migrate and persist as nodules lining the ventricular surface"
Original description of the periventricular nodular heterotopia phenotype in FLNA-deficient patients.
Mild Intellectual Disability Rare Intellectual disability (HP:0001249)
22 of 24 patients with available educational data attended regular school and obtained professional education.
Show evidence (1 reference)
PMID:26471271 PARTIAL Human Clinical
"22 of 24 patients with available educational data were able to attend regular school and obtain professional education according to age"
Most patients have normal cognition; intellectual disability is not a predominant feature.
Respiratory 1
Progressive Lung Disease Occasional Abnormal pulmonary interstitial morphology (HP:0006530)
Show evidence (2 references)
PMID:28457522 SUPPORT Human Clinical
"All patients had pulmonary arterial hypertension and chronic respiratory failure requiring tracheostomy and escalating levels of ventilator support before transplantation."
Describes severe pulmonary phenotype in FLNA-PVNH infants.
PMID:30547349 SUPPORT Human Clinical
"The respiratory phenotype in the form of childhood interstitial lung disease is a recently recognised clinical consequence of loss-of-function FLNA mutation."
Review confirming lung disease as an emerging FLNA phenotype.
🧬

Genetic Associations

1
FLNA Loss-of-Function Variants (Pathogenic Variants)
X-linked Dominant
Show evidence (3 references)
PMID:26471271 SUPPORT Human Clinical
"Thirty-nine different FLNA mutations were observed, they are mainly truncating (37/39) and distributed throughout the entire coding region."
Large cohort characterizing the mutation spectrum in FLNA-PVNH.
PMID:9883725 SUPPORT Human Clinical
"hemizygous males die embryonically"
Original paper establishing prenatal male lethality with null FLNA.
PMID:20301392 SUPPORT Human Clinical
"About 50% of affected females inherit the pathogenic variant from their mother and at least 50% have a de novo pathogenic variant."
GeneReviews confirms approximately equal de novo and inherited cases.
💊

Treatments

4
Antiepileptic Drug Therapy
Action: Antiepileptic drug therapy Ontology label: Pharmacotherapy NCIT:C15986
Treatment of epilepsy generally follows principles for a seizure disorder caused by a known structural brain abnormality. Anti-seizure medication is typically selected based on teratogenic risk, tolerability, and efficacy.
Show evidence (1 reference)
PMID:20301392 SUPPORT Human Clinical
"Treatment of epilepsy generally follows principles for a seizure disorder caused by a known structural brain abnormality."
GeneReviews management guidance for seizure treatment.
Cardiovascular Surveillance
Action: Cardiovascular monitoring Ontology label: supportive care MAXO:0000950
Regular cardiology evaluations with echocardiogram, stress testing, and cardiac MRI to monitor for aortic dilation, valvular dystrophy, and dissection risk. Good blood pressure control is recommended.
Show evidence (2 references)
PMID:20301392 SUPPORT Human Clinical
"Cardiology evaluations, echocardiogram, stress testing, and cardiac MRI as recommended by cardiologist."
GeneReviews surveillance recommendations for cardiovascular monitoring.
PMID:26471271 SUPPORT Human Clinical
"intensely delaying appropriate medical surveillance for potentially life threatening cardiovascular complications"
Emphasizes the importance of early cardiovascular surveillance after genetic diagnosis.
Lung Transplantation
Action: Lung transplantation Ontology label: organ transplantation MAXO:0010039
Lung transplantation is a viable therapeutic option for infants with FLNA-associated progressive respiratory failure. Five of six patients survived with unrestricted lives post-transplant.
Show evidence (1 reference)
PMID:28457522 SUPPORT Human Clinical
"All 6 patients survived initial lung transplantation"
Demonstrates lung transplantation as viable treatment for FLNA-associated progressive lung disease.
Genetic Counseling
Action: Genetic counseling Ontology label: genetic counseling MAXO:0000079
Genetic counseling regarding X-linked inheritance, high prenatal lethality in males, recurrence risk, and prenatal testing options. Evaluation of at-risk relatives for cardiovascular complications is recommended even in neurologically asymptomatic individuals.
Show evidence (1 reference)
PMID:20301392 SUPPORT Human Clinical
"it is appropriate to evaluate the older and younger at-risk relatives of an affected individual in order to identify as early as possible those who would benefit from echocardiogram and cardiac MRI"
GeneReviews emphasizes cascade screening of at-risk relatives.
{ }

Source YAML

click to show 
name: Periventricular Nodular Heterotopia
creation_date: "2026-04-04T00:00:00Z"
updated_date: "2026-04-07T02:27:09Z"
description: >-
  Periventricular nodular heterotopia (PVNH) is a neuronal migration disorder
  characterized by nodules of gray matter lining the lateral ventricles due to
  failure of neurons to migrate from the ventricular zone to the cortex during
  embryonic development. The X-linked dominant form, caused by loss-of-function
  variants in FLNA (filamin A), predominantly affects females, as hemizygous
  males typically die in utero. Clinical features include epilepsy (often the
  presenting symptom), normal to borderline intelligence, cardiovascular
  anomalies (patent ductus arteriosus, progressive valvular dystrophy, aortic
  dissection), chronic obstructive lung disease, gastrointestinal dysmotility,
  coagulopathy, and joint hypermobility. Seizures typically begin at variable
  age of onset and may be difficult to treat. A concerning median diagnostic
  latency of 17 to 20 years between seizure onset and genetic diagnosis has
  been reported.
category: Genetic
parents:
- Neuronal Migration Disorder
- Malformation of Cortical Development
disease_term:
  preferred_term: periventricular nodular heterotopia
  term:
    id: MONDO:0010233
    label: heterotopia, periventricular, X-linked dominant
prevalence:
- population: Global
  percentage: Rare
inheritance:
- name: X-linked Dominant
  inheritance_term:
    preferred_term: X-linked dominant inheritance
    term:
      id: HP:0001423
      label: X-linked dominant inheritance
pathophysiology:
- name: FLNA Loss of Function and Neuronal Migration Failure
  description: >-
    Filamin A (FLNA) is a large actin-cross-linking phosphoprotein that
    transduces ligand-receptor binding into actin reorganization and is
    required for locomotion of many cell types. In the developing cerebral
    cortex, FLNA shows high-level expression and is required for neuronal
    migration from the ventricular zone to the cortical plate. Loss-of-function
    variants in FLNA disrupt actin cytoskeletal dynamics, preventing neurons
    from migrating to the cortex. These neurons persist as nodules lining the
    ventricular surface.
  genes:
  - preferred_term: FLNA
    term:
      id: hgnc:3754
      label: FLNA
  molecular_functions:
  - preferred_term: actin filament binding
    term:
      id: GO:0051015
      label: actin filament binding
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Radial glial cell
    term:
      id: CL:0000681
      label: radial glial cell
  biological_processes:
  - preferred_term: Neuronal migration
    term:
      id: GO:0001764
      label: neuron migration
  - preferred_term: Actin cytoskeleton organization
    term:
      id: GO:0030036
      label: actin cytoskeleton organization
  - preferred_term: Cell-matrix adhesion
    term:
      id: GO:0007160
      label: cell-matrix adhesion
  locations:
  - preferred_term: Cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  - preferred_term: Lateral ventricle
    term:
      id: UBERON:0002285
      label: telencephalic ventricle
  evidence:
  - reference: PMID:9883725
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the X-linked dominant human disorder periventricular heterotopia
      (PH), many neurons fail to migrate and persist as nodules lining the
      ventricular surface.
    explanation: >-
      The landmark paper identifying FLNA (then FLN1) as the causative gene
      for X-linked periventricular heterotopia, demonstrating its role in
      neuronal migration.
  - reference: PMID:9883725
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We have identified the PH gene as filamin 1 (FLN1), which encodes an
      actin-cross-linking phosphoprotein that transduces ligand-receptor
      binding into actin reorganization, and which is required for
      locomotion of many cell types.
    explanation: >-
      Establishes FLNA as an actin-binding protein required for cell
      locomotion, explaining the neuronal migration failure mechanism.
  - reference: PMID:14988809
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two disorders, periventricular nodular heterotopia (PVNH) and a group
      of skeletal dysplasias belonging to the oto-palato-digital (OPD)
      spectrum, are caused by FLNA mutations. They are considered mutually
      exclusive because of the different presumed effects of the respective
      FLNA gene mutations, leading to loss of function (PVNH) and gain of
      function (OPD), respectively.
    explanation: >-
      Zenker et al. 2004 describes a patient with dual PVNH and FMD
      phenotype from a single FLNA mutation producing both loss-of-function
      and gain-of-function transcripts, reinforcing the mechanistic
      distinction between PVNH (loss-of-function) and OPD (gain-of-function).
  downstream:
  - target: Epileptogenesis from Heterotopic Nodules
- name: Epileptogenesis from Heterotopic Nodules
  description: >-
    The ectopic gray matter nodules lining the ventricles form abnormal
    neuronal circuits that are intrinsically epileptogenic, generating
    seizures due to aberrant synaptic connectivity and network organization.
    Most affected females initially present with difficult to treat seizures
    at variable age of onset.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  locations:
  - preferred_term: Lateral ventricle
    term:
      id: UBERON:0002285
      label: telencephalic ventricle
  evidence:
  - reference: PMID:26471271
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most affected females are reported to initially present with
      difficult to treat seizures at variable age of onset.
    explanation: >-
      Large cohort study of 47 FLNA-PVNH patients confirming seizures as
      the most common presenting symptom.
- name: Cardiovascular Connective Tissue Dysfunction
  description: >-
    FLNA is widely expressed in cardiovascular tissues where it plays a role
    in vascular integrity and cardiac valve development. Loss of FLNA function
    leads to cardiovascular abnormalities including patent ductus arteriosus,
    progressive dystrophic cardiac valve disease, and aortic dissection.
    Severe ascending aortic dilation with aortic regurgitation has been
    observed in patients even after lung transplantation.
  cell_types:
  - preferred_term: Endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: Smooth muscle cell
    term:
      id: CL:0000192
      label: smooth muscle cell
  biological_processes:
  - preferred_term: Heart valve development
    term:
      id: GO:0003170
      label: heart valve development
  - preferred_term: Vascular development
    term:
      id: GO:0001944
      label: vasculature development
  locations:
  - preferred_term: Heart
    term:
      id: UBERON:0000948
      label: heart
  - preferred_term: Aorta
    term:
      id: UBERON:0000947
      label: aorta
  evidence:
  - reference: PMID:9883725
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Females with PH present with epilepsy and other signs, including
      patent ductus arteriosus and coagulopathy
    explanation: >-
      Original description establishing cardiovascular involvement (PDA)
      as part of the FLNA-PVNH phenotype.
  - reference: PMID:28457522
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in all patients, severe ascending aortic dilation has been observed
      with aortic regurgitation
    explanation: >-
      Documents progressive aortic dilation in FLNA-PVNH patients who
      underwent lung transplantation, highlighting cardiovascular
      complications.
- name: Progressive Lung Disease
  description: >-
    A recently recognized phenotypic consequence of loss-of-function FLNA
    mutations is childhood-onset interstitial and obstructive lung disease.
    Infants may present with progressive respiratory failure requiring
    escalating ventilator support, pulmonary arterial hypertension, and
    in severe cases, lung transplantation. Rare surviving males with
    residual protein function can present with severe lung disease.
  cell_types:
  - preferred_term: Pulmonary alveolar type 2 cell
    term:
      id: CL:0002063
      label: pulmonary alveolar type 2 cell
  biological_processes:
  - preferred_term: Lung development
    term:
      id: GO:0030324
      label: lung development
  locations:
  - preferred_term: Lung
    term:
      id: UBERON:0002048
      label: lung
  evidence:
  - reference: PMID:28457522
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Respiratory failure secondary to progressive obstructive lung disease
      during infancy may be the presenting phenotype of FLNA-associated
      periventricular nodular heterotopia.
    explanation: >-
      Describes a cohort of 6 female infants with FLNA loss-of-function
      who presented with progressive respiratory failure requiring lung
      transplantation.
  - reference: PMID:30547349
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The respiratory phenotype in the form of childhood interstitial lung
      disease is a recently recognised clinical consequence of
      loss-of-function FLNA mutation.
    explanation: >-
      Review confirming interstitial lung disease as an emerging phenotype
      of FLNA loss-of-function mutations.
phenotypes:
- category: Neurological
  name: Epilepsy
  frequency: Very frequent
  description: >-
    Seizures are the most common presenting symptom, typically focal in
    onset and often difficult to treat. Age of onset is variable. A median
    diagnostic latency of 17 to 20 years between seizure onset and genetic
    diagnosis has been reported.
  phenotype_term:
    preferred_term: Epilepsy
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:26471271
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most affected females are reported to initially present with
      difficult to treat seizures at variable age of onset.
    explanation: >-
      Large cohort confirming seizures as the predominant presenting
      feature in FLNA-PVNH.
  - reference: PMID:26471271
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a concerning median diagnostic latency of 17 to 20 years was noted
      between seizure onset and the genetic diagnosis
    explanation: >-
      Highlights the significant delay between symptom onset and molecular
      diagnosis.
- category: Neurological
  name: Periventricular Nodular Heterotopia
  frequency: Very frequent
  description: >-
    Bilateral nodules of gray matter along the walls of the lateral
    ventricles, visible on MRI. The hallmark structural abnormality.
  phenotype_term:
    preferred_term: Periventricular nodular heterotopia
    term:
      id: HP:0032388
      label: Periventricular nodular heterotopia
  evidence:
  - reference: PMID:9883725
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      many neurons fail to migrate and persist as nodules lining the
      ventricular surface
    explanation: >-
      Original description of the periventricular nodular heterotopia
      phenotype in FLNA-deficient patients.
- category: Neurological
  name: Mild Intellectual Disability
  frequency: Rare
  description: >-
    Most females with FLNA-PVNH have normal intelligence (approximately 92%
    attend regular school). Mild intellectual disability or learning
    difficulties are reported in a minority.
  notes: >-
    22 of 24 patients with available educational data attended regular
    school and obtained professional education.
  phenotype_term:
    preferred_term: Mild intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:26471271
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      22 of 24 patients with available educational data were able to
      attend regular school and obtain professional education according
      to age
    explanation: >-
      Most patients have normal cognition; intellectual disability is
      not a predominant feature.
- category: Cardiovascular
  name: Patent Ductus Arteriosus
  frequency: Frequent
  description: >-
    Persistence of the ductus arteriosus after birth is a common
    cardiovascular finding.
  phenotype_term:
    preferred_term: Patent ductus arteriosus
    term:
      id: HP:0001643
      label: Patent ductus arteriosus
  evidence:
  - reference: PMID:9883725
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Females with PH present with epilepsy and other signs, including
      patent ductus arteriosus and coagulopathy
    explanation: >-
      Patent ductus arteriosus identified as part of the PVNH phenotype
      in the original gene discovery paper.
  - reference: PMID:20301392
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      congenital heart disease (patent ductus arteriosus, atrial and
      ventricular septal defects), valvular dystrophy
    explanation: >-
      GeneReviews confirms PDA and other cardiac defects as part of the
      FLNA deficiency spectrum.
- category: Cardiovascular
  name: Progressive Valvular Dystrophy and Aortic Dilation
  frequency: Occasional
  description: >-
    Progressive dystrophic cardiac valve disease and aortic dissection are
    potentially life-threatening cardiovascular complications. Severe
    ascending aortic dilation with aortic regurgitation has been observed.
  phenotype_term:
    preferred_term: Aortic dilation
    term:
      id: HP:0004942
      label: Aortic aneurysm
  evidence:
  - reference: PMID:26471271
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Distinct associated extracerebral findings have been observed and
      may help to establish the diagnosis including patent ductus
      arteriosus Botalli, progressive dystrophic cardiac valve disease
      and aortic dissection
    explanation: >-
      Large cohort confirms progressive cardiovascular complications
      including valvular dystrophy and aortic dissection.
  - reference: PMID:28457522
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in all patients, severe ascending aortic dilation has been observed
      with aortic regurgitation
    explanation: >-
      Progressive aortic dilation observed even after lung transplant,
      highlighting ongoing cardiovascular risk.
- category: Respiratory
  name: Progressive Lung Disease
  frequency: Occasional
  description: >-
    Childhood-onset interstitial and obstructive lung disease is a recently
    recognized feature. Infants may present with progressive respiratory
    failure, pulmonary arterial hypertension, and chronic respiratory
    failure requiring tracheostomy.
  phenotype_term:
    preferred_term: Interstitial lung disease
    term:
      id: HP:0006530
      label: Abnormal pulmonary interstitial morphology
  evidence:
  - reference: PMID:28457522
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients had pulmonary arterial hypertension and chronic
      respiratory failure requiring tracheostomy and escalating levels
      of ventilator support before transplantation.
    explanation: >-
      Describes severe pulmonary phenotype in FLNA-PVNH infants.
  - reference: PMID:30547349
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The respiratory phenotype in the form of childhood interstitial lung
      disease is a recently recognised clinical consequence of
      loss-of-function FLNA mutation.
    explanation: >-
      Review confirming lung disease as an emerging FLNA phenotype.
- category: Musculoskeletal
  name: Joint Hypermobility
  frequency: Frequent
  description: >-
    Generalized joint hypermobility is a common connective tissue feature.
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: PMID:20301392
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      joint hypermobility
    explanation: >-
      GeneReviews lists joint hypermobility as part of FLNA deficiency
      spectrum.
- category: Hematologic
  name: Coagulopathy
  frequency: Occasional
  description: >-
    Bleeding diathesis and macrothrombocytopenia are reported, possibly
    related to the role of filamin A in platelet function.
  phenotype_term:
    preferred_term: Abnormal bleeding
    term:
      id: HP:0001892
      label: Abnormal bleeding
  evidence:
  - reference: PMID:9883725
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Females with PH present with epilepsy and other signs, including
      patent ductus arteriosus and coagulopathy
    explanation: >-
      Coagulopathy identified in the original FLNA-PVNH gene discovery.
  - reference: PMID:20301392
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      macrothrombocytopenia
    explanation: >-
      GeneReviews confirms macrothrombocytopenia as part of FLNA deficiency.
- category: Gastrointestinal
  name: Gastrointestinal Dysmotility
  frequency: Occasional
  description: >-
    Chronic constipation and gastrointestinal dysmotility including
    intestinal obstruction can occur.
  phenotype_term:
    preferred_term: Chronic constipation
    term:
      id: HP:0012450
      label: Chronic constipation
  evidence:
  - reference: PMID:26471271
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      chronic constipation
    explanation: >-
      Large PVNH cohort identifies chronic constipation as an associated
      feature.
  - reference: PMID:20301392
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      gastrointestinal dysmotility and obstruction
    explanation: >-
      GeneReviews confirms GI dysmotility as part of FLNA deficiency.
genetic:
- name: FLNA Loss-of-Function Variants
  association: Pathogenic Variants
  gene_term:
    preferred_term: FLNA
    term:
      id: hgnc:3754
      label: FLNA
  inheritance:
  - name: X-linked Dominant
    inheritance_term:
      preferred_term: X-linked dominant inheritance
      term:
        id: HP:0001423
        label: X-linked dominant inheritance
  features: >-
    Heterozygous loss-of-function variants in females; hemizygous males
    typically lethal prenatally. Mutations are mainly truncating and
    distributed throughout the entire coding region. About 50% inherited,
    at least 50% de novo.
  notes: >-
    Rare surviving males with somatic mosaicism or hypomorphic alleles have
    been reported.
  evidence:
  - reference: PMID:26471271
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thirty-nine different FLNA mutations were observed, they are mainly
      truncating (37/39) and distributed throughout the entire coding
      region.
    explanation: >-
      Large cohort characterizing the mutation spectrum in FLNA-PVNH.
  - reference: PMID:9883725
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      hemizygous males die embryonically
    explanation: >-
      Original paper establishing prenatal male lethality with null FLNA.
  - reference: PMID:20301392
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      About 50% of affected females inherit the pathogenic variant from
      their mother and at least 50% have a de novo pathogenic variant.
    explanation: >-
      GeneReviews confirms approximately equal de novo and inherited cases.
treatments:
- name: Antiepileptic Drug Therapy
  description: >-
    Treatment of epilepsy generally follows principles for a seizure disorder
    caused by a known structural brain abnormality. Anti-seizure medication
    is typically selected based on teratogenic risk, tolerability, and
    efficacy.
  treatment_term:
    preferred_term: Antiepileptic drug therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:20301392
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment of epilepsy generally follows principles for a seizure
      disorder caused by a known structural brain abnormality.
    explanation: >-
      GeneReviews management guidance for seizure treatment.
- name: Cardiovascular Surveillance
  description: >-
    Regular cardiology evaluations with echocardiogram, stress testing,
    and cardiac MRI to monitor for aortic dilation, valvular dystrophy,
    and dissection risk. Good blood pressure control is recommended.
  treatment_term:
    preferred_term: Cardiovascular monitoring
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:20301392
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cardiology evaluations, echocardiogram, stress testing, and cardiac
      MRI as recommended by cardiologist.
    explanation: >-
      GeneReviews surveillance recommendations for cardiovascular monitoring.
  - reference: PMID:26471271
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      intensely delaying appropriate medical surveillance for potentially
      life threatening cardiovascular complications
    explanation: >-
      Emphasizes the importance of early cardiovascular surveillance after
      genetic diagnosis.
- name: Lung Transplantation
  description: >-
    Lung transplantation is a viable therapeutic option for infants with
    FLNA-associated progressive respiratory failure. Five of six patients
    survived with unrestricted lives post-transplant.
  treatment_term:
    preferred_term: Lung transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
  evidence:
  - reference: PMID:28457522
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All 6 patients survived initial lung transplantation
    explanation: >-
      Demonstrates lung transplantation as viable treatment for
      FLNA-associated progressive lung disease.
- name: Genetic Counseling
  description: >-
    Genetic counseling regarding X-linked inheritance, high prenatal lethality
    in males, recurrence risk, and prenatal testing options. Evaluation of
    at-risk relatives for cardiovascular complications is recommended even
    in neurologically asymptomatic individuals.
  treatment_term:
    preferred_term: Genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:20301392
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      it is appropriate to evaluate the older and younger at-risk
      relatives of an affected individual in order to identify as early
      as possible those who would benefit from echocardiogram and cardiac
      MRI
    explanation: >-
      GeneReviews emphasizes cascade screening of at-risk relatives.
datasets: []
references:
- reference: PMID:20301392
  title: "FLNA Deficiency."
  tags:
  - GeneReviews
  findings: []
📚

References & Deep Research

References

1
PMID:20301392
FLNA Deficiency.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 49 citations 2026-04-04T12:39:37.122784

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Periventricular Nodular Heterotopia
  • MONDO ID: (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on Periventricular Nodular Heterotopia covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Disease Characteristics Report: Periventricular Nodular Heterotopia (PVNH)

Executive summary

Periventricular nodular heterotopia (PVNH; also PNH) is a malformation of cortical development caused by abnormal neuronal migration, with heterotopic gray-matter nodules lining the lateral ventricular walls and a strong association with epilepsy and variable neurodevelopmental outcomes. Classical PVNH is most often due to X-linked loss-of-function (LoF) variants in FLNA, but PVNH is genetically heterogeneous, with multiple additional Mendelian genes and copy-number variants (CNVs) implicated. Recent 2023–2024 work expanded causal gene/phenotype space (e.g., ARF1, TAOK1) and provided experimentally testable pathway hypotheses (e.g., autophagy/AMPK modulation in DCHS1/FAT4-related periventricular heterotopia) with a potential repurposing angle for metformin in model systems. (agathe2023arf1relateddisorderphenotypic pages 1-2, cavalli2024heterozygoustruncatingvariant pages 1-3, bressan2023metforminrescuesmigratory pages 1-2)

1. Disease information

1.1 Disease overview (definition and current understanding)

PVNH/PNH is a neuronal migration disorder in which subsets of neurons fail to migrate into the developing cerebral cortex and instead “remain as nodules lining the ventricular surface,” producing periventricular nodules (typically adjacent to the lateral ventricles). (parrini2004mosaicmutationsof pages 1-2)

A practical MRI definition used clinically is the presence of subependymal/periventricular nodules with signal similar to gray matter along the lateral ventricle lining, frequently bilateral and often anterior predominant in FLNA-associated disease. (fernandes2024periventricularnodularheterotopias pages 1-2, lu2022theclinicaland pages 1-8)

1.2 Key identifiers

  • OMIM (disease): Periventricular nodular heterotopia / PNH 300049 (parrini2004mosaicmutationsof pages 1-2, gerlevik2022computationalanalysisof pages 1-2)
  • OMIM (gene): FLNA/FLN1 *300017 (parrini2004mosaicmutationsof pages 1-2)
  • MONDO / Orphanet / ICD-10/ICD-11 / MeSH: Not available in the retrieved evidence corpus for this run; should be added via direct lookup in MONDO/Orphanet/ICD/MeSH resources outside the current tool context. (parrini2004mosaicmutationsof pages 1-2)

1.3 Synonyms and alternative names

Commonly used synonyms include: - Periventricular heterotopia / periventricular nodular heterotopia (PVNH/PNH) (parrini2004mosaicmutationsof pages 1-2, paliotti2022epilepsyinindividualsa pages 8-13) - Subependymal heterotopia(s) (fernandes2024periventricularnodularheterotopias pages 1-2)

1.4 Evidence source type

This report synthesizes evidence from: - Aggregated disease-level cohorts and cross-sectional/retrospective cohorts (e.g., 24-person FLNA LoF cohort; 47-person FLNA-PVNH cohort; 100-person PVNH epilepsy cohort) (rijckmans2024counselingindividualswith pages 1-3, lange201547patientswith pages 1-2, paliotti2022epilepsyinindividualsa pages 26-31) - Primary experimental studies using patient-derived cells/organoids and xenografts (e.g., DCHS1/FAT4 models) (bressan2023metforminrescuesmigratory pages 1-2, bressan2023metforminrescuesmigratory pages 9-10) - ClinicalTrials.gov registry entries for research implementations involving PVNH (NCT00552045 chunk 1, NCT05696912 chunk 1)

2. Etiology

2.1 Disease causal factors

Primary causes are genetic, centered on disruption of neuronal migration and related developmental programs.

  • Classical/X-linked PVNH: X-linked dominant LoF variants in FLNA are a major cause and show strong female predominance; hemizygous male viability is reduced with high prenatal/perinatal lethality, though surviving males occur (often via mosaicism or hypomorphic alleles). (lange201547patientswith pages 1-2, cannaerts2018flnamutationsin pages 1-3, lange201547patientswith pages 4-6)
  • Autosomal dominant PVNH syndromes: De novo ARF1 variants were identified in a 17-individual cohort with a phenotype including PVNH, seizures, microcephaly, and intellectual disability. (agathe2023arf1relateddisorderphenotypic pages 1-1)
  • Other Mendelian causes: PVNH genetic heterogeneity includes genes implicated in vesicle trafficking (e.g., ARFGEF2) and multiple other loci; CNVs are also reported contributors. (paliotti2022epilepsyinindividuals pages 17-22, lange201547patientswith pages 1-2)

2.2 Risk factors

Genetic risk factors (examples supported by retrieved evidence)

  • FLNA LoF: most frequent cause of bilateral/anterior-predominant PVNH. (lange201547patientswith pages 1-2, lu2022theclinicaland pages 1-8)
  • ARF1 (de novo): autosomal dominant NDD including PVNH. (agathe2023arf1relateddisorderphenotypic pages 1-1)
  • TAOK1 (heterozygous truncating): reported association with PVNH in a child with TAOK1-related NDD. (cavalli2024heterozygoustruncatingvariant pages 1-3)
  • DCHS1/FAT4: periventricular heterotopia/gray matter heterotopia with demonstrated migration defects in patient-derived models. (bressan2023metforminrescuesmigratory pages 1-2)

Environmental risk factors

Not established in the retrieved evidence corpus; PVNH is predominantly treated as a genetic neurodevelopmental disorder in the included sources. (parrini2004mosaicmutationsof pages 1-2, agathe2023arf1relateddisorderphenotypic pages 1-2)

2.3 Protective factors

No validated protective variants or environmental protective factors were identified in the retrieved evidence corpus. (parrini2004mosaicmutationsof pages 1-2)

2.4 Gene–environment interactions

Not addressed in the retrieved evidence corpus. (parrini2004mosaicmutationsof pages 1-2)

3. Phenotypes (clinical spectrum)

The phenotype is variable and depends on genetic etiology and imaging pattern (isolated PVNH vs PVNH-plus with additional malformations). (paliotti2022epilepsyinindividualsa pages 26-31)

3.1 Core neurologic phenotypes

  • Epilepsy/seizures (HP:0001250): In a 100-person PVNH cohort, 70/100 (70%) had epilepsy. (paliotti2022epilepsyinindividualsa pages 17-22, paliotti2022epilepsyinindividuals pages 17-22)
  • Seizure onset: Mean 7.9 years (range day 1–41 years) in the 100-person cohort. (paliotti2022epilepsyinindividualsa pages 26-31)
  • EEG abnormalities: 95% (92/99) abnormal EEG in the 100-person cohort, including focal, multifocal, and generalized interictal epileptiform discharges. (paliotti2022epilepsyinindividualsa pages 26-31)

3.2 Neurodevelopmental and behavioral phenotypes

In the 100-person cohort: - Delayed milestones (HP:0001263): 43% (paliotti2022epilepsyinindividualsa pages 26-31) - Learning/communication difficulties (HP:0001328 / HP:0000750): 62% (paliotti2022epilepsyinindividualsa pages 26-31) - Autism diagnosis / autistic behavior (HP:0000729): 15% (paliotti2022epilepsyinindividualsa pages 26-31)

3.3 Systemic phenotypes in FLNA LoF (“FLNA deficiency”)

In a 24-individual FLNA LoF cohort: - Epilepsy: 84% with median onset 17 years; drug resistance 42% among those with seizure data. (rijckmans2024counselingindividualswith pages 5-6) - Cardiovascular involvement (HP:0001626): 56% (9/16 with comprehensive cardiology evaluation). (rijckmans2024counselingindividualswith pages 5-6) - Constipation/GI dysmotility (HP:0002019): constipation noted at cohort level (~25% in extracted cohort discussion) and severe cases including chronic intestinal pseudo-obstruction (CIPO). (rijckmans2024counselingindividualswith pages 6-8, rijckmans2024counselingindividualswith pages 5-6) - Thrombocytopenia (HP:0001873): reported in two cohort members. (rijckmans2024counselingindividualswith pages 5-6)

3.4 Phenotype frequencies and suggested HPO terms (curation-ready)

A structured phenotype table with HPO mappings and cohort frequencies is provided below.

Feature Suggested HPO term(s) Frequency/statistic Cohort/source details (n, population) Notes Citation IDs
Periventricular nodular heterotopia on MRI HP:0002138 Periventricular heterotopia 23/24 (95.8%) FLNA loss-of-function cohort, 24 index patients Core neuroimaging feature in FLNA deficiency cohort (rijckmans2024counselingindividualswith pages 1-3, rijckmans2025"phenotypicandgenotypic pages 1-6)
Epilepsy HP:0001250 Seizure, HP:0002123 Generalized myoclonic seizure, HP:0007359 Focal-onset seizure 16/19 (84%) FLNA loss-of-function cohort, seizure data available for 19/24 Median seizure onset 17 years in this cohort (rijckmans2025"phenotypicandgenotypic pages 6-10, rijckmans2024counselingindividualswith pages 5-6)
Cardiovascular involvement HP:0001626 Abnormality of the cardiovascular system, HP:0001659 Congenital heart defect, HP:0001644 Dilatation of the aorta 9/16 (56%) FLNA loss-of-function cohort, 16/24 had comprehensive cardiology evaluation Valve insufficiency most common; aortic root involvement reported (rijckmans2025"phenotypicandgenotypic pages 6-10, rijckmans2024counselingindividualswith pages 5-6, rijckmans2024counselingindividualswith pages 6-8)
Constipation / GI dysmotility HP:0002019 Constipation, HP:0012602 Intestinal pseudo-obstruction 25% constipation; 1 case CIPO requiring colectomy FLNA loss-of-function cohort, 24 index patients Constipation likely underreported in earlier literature (rijckmans2024counselingindividualswith pages 6-8, rijckmans2025"phenotypicandgenotypic pages 10-14)
Thrombocytopenia HP:0001873 Thrombocytopenia 2 cases FLNA loss-of-function cohort, 24 index patients Hematologic involvement recognized but incompletely quantified (rijckmans2024counselingindividualswith pages 5-6, rijckmans2024counselingindividualswith pages 6-8)
Posterior fossa anomaly / mega cisterna magna on MRI HP:0002280 Enlarged cisterna magna, HP:0000936 Posterior fossa abnormality 33% FLNA loss-of-function cohort, 24 index patients MRI-associated anomaly in addition to PVNH (rijckmans2024counselingindividualswith pages 5-6)
Corpus callosum abnormality HP:0001273 Abnormality of the corpus callosum 18% FLNA loss-of-function cohort, 24 index patients Structural MRI-associated anomaly (rijckmans2024counselingindividualswith pages 5-6)
Seizure-free carriers HP:0001250 Seizure 10 carriers seizure-free; median age 19.7 years FLNA-associated PVNH cohort, 47 patients Shows incomplete penetrance for epilepsy (lange201547patientswith pages 1-2)
Mainstream schooling / preserved educational attainment HP:0000729 Autistic behavior, HP:0001249 Intellectual disability 22/24 attended regular school FLNA-associated PVNH cohort, educational data available for 24 patients Supports generally preserved cognition in many FLNA-PVNH patients (lange201547patientswith pages 1-2)
Diagnostic latency HP:0010524 Delayed diagnosis Median 17-20 years FLNA-associated PVNH cohort, 47 patients Long delay may postpone surveillance for cardiovascular complications (lange201547patientswith pages 1-2)
Delayed developmental milestones HP:0001263 Global developmental delay, HP:0011344 Severe global developmental delay 43% PVNH cohort, n=100 Mixed-genetic/clinical PVNH cohort (paliotti2022epilepsyinindividualsa pages 26-31)
Learning or communication difficulties HP:0001328 Learning disability, HP:0000750 Delayed speech and language development 62% PVNH cohort, n=100 Reflects common neurodevelopmental burden beyond seizures (paliotti2022epilepsyinindividualsa pages 26-31)
Autism spectrum disorder HP:0000729 Autistic behavior 15/100 (15%) PVNH cohort, n=100 Behavioral/neurodevelopmental comorbidity (paliotti2022epilepsyinindividualsa pages 26-31)
Epilepsy overall HP:0001250 Seizure 70/100 (70%) PVNH cohort, n=100 Broad PVNH cohort; epilepsy common but not universal (paliotti2022epilepsyinindividualsa pages 17-22, paliotti2022epilepsyinindividuals pages 17-22)
Self-limited epilepsy course HP:0001250 Seizure 10% PVNH cohort, n=100 Indicates a minority have relatively benign seizure trajectory (paliotti2022epilepsyinindividualsa pages 26-31)
Pharmacoresponsive epilepsy HP:0001250 Seizure 35% PVNH cohort, n=100 Seizure-free mean 4.5 years in responders (paliotti2022epilepsyinindividualsa pages 26-31)
Uncontrolled seizures HP:0001250 Seizure 55% PVNH cohort, n=100 Highlights substantial refractory burden (paliotti2022epilepsyinindividualsa pages 26-31)
Drug-resistant epilepsy HP:0001250 Seizure, HP:0032794 Drug-resistant epilepsy 23% PVNH cohort, n=100 Multiple bilateral PVNH had highest drug-resistance in this cohort (paliotti2022epilepsyinindividualsa pages 26-31)
Corpus callosum agenesis/dysgenesis HP:0001274 Agenesis of corpus callosum, HP:0001273 Abnormality of the corpus callosum 28% PVNH-Plus subgroup within PVNH cohort, n=100 overall One of the most frequent associated brain malformations (paliotti2022epilepsyinindividualsa pages 26-31)
Ventricular abnormalities HP:0002119 Ventriculomegaly 20% PVNH-Plus subgroup within PVNH cohort, n=100 overall Associated imaging abnormality (paliotti2022epilepsyinindividualsa pages 26-31)
Polymicrogyria HP:0002126 Polymicrogyria 18% PVNH-Plus subgroup within PVNH cohort, n=100 overall Co-occurring malformation of cortical development (paliotti2022epilepsyinindividualsa pages 26-31)
Brain cysts HP:0000932 Cerebral cyst 16% PVNH-Plus subgroup within PVNH cohort, n=100 overall Associated structural brain finding (paliotti2022epilepsyinindividualsa pages 26-31)
Hippocampal abnormality HP:0012083 Abnormality of the hippocampus 13% PVNH-Plus subgroup within PVNH cohort, n=100 overall Relevant to epileptogenic network considerations (paliotti2022epilepsyinindividualsa pages 26-31)

Table: This table summarizes key clinical and imaging features of periventricular nodular heterotopia with frequencies drawn from major cohorts, emphasizing FLNA-related multisystem disease and epilepsy outcomes in broader PVNH populations. It is useful for structured phenotype curation and knowledge base entry building.

3.5 Quality-of-life impact

Validated QoL instruments (e.g., SF-36, EQ-5D, PROMIS) were not reported in the retrieved evidence corpus. Functional impact is nevertheless strongly suggested by the high proportion of individuals with uncontrolled or drug-resistant seizures (55% uncontrolled; 23% drug-resistant in one 100-person cohort) and by multisystem FLNA-related complications (e.g., cardiovascular disease requiring surveillance). (paliotti2022epilepsyinindividualsa pages 26-31, rijckmans2024counselingindividualswith pages 6-8)

4. Genetic / molecular information

4.1 Causal genes (representative, evidence-backed)

  • FLNA (X-linked dominant): most frequent cause of classical bilateral/anterior-predominant PVNH. (lange201547patientswith pages 1-2, lu2022theclinicaland pages 1-8)
  • ARF1 (autosomal dominant, de novo): neurodevelopmental disorder with PVNH, microcephaly, seizures, and intellectual disability (international cohort, n=17). (agathe2023arf1relateddisorderphenotypic pages 1-1)
  • TAOK1 (autosomal dominant, typically de novo): truncating variant associated with PVNH in a reported case; supports a role in neuronal migration disorders. (cavalli2024heterozygoustruncatingvariant pages 1-3)
  • DCHS1 / FAT4: periventricular heterotopia/gray matter heterotopia with experimentally demonstrated migration/autophagy phenotypes. (bressan2023metforminrescuesmigratory pages 1-2)
  • ARFGEF2: mentioned as PVNH-associated, mechanistically tied to vesicle trafficking and in some contexts associated with microcephaly plus PVNH. (gerlevik2022computationalanalysisof pages 1-2, agathe2023arf1relateddisorderphenotypic pages 1-2)

4.2 Pathogenic variant classes and functional consequences

  • FLNA: Variants are frequently truncating LoF; in one 47-patient FLNA-PVNH cohort, mutations were “mainly truncating (37/39).” (lange201547patientswith pages 1-2)
  • Mosaicism and male survival: Surviving males in one FLNA cohort carried truncating variants in mosaic state in blood (~40–60% mutant alleles). (lange201547patientswith pages 4-6)
  • Germline mosaicism: A family report concluded “evidence for germline mosaicism in filamin A-associated periventricular nodular heterotopia,” relevant when parental blood testing is negative. (lapointe2014germlinemosaicismin pages 1-3)

4.3 Modifier genes / epigenetics

Not established in the retrieved evidence corpus.

4.4 Chromosomal abnormalities / CNVs

CNVs are part of the genetic heterogeneity and are detected in clinical cohorts using chromosomal microarray (CMA) and MLPA (for FLNA). In a 100-person cohort, CMA was used in 20 individuals and CNVs were found in five (three pathogenic). (paliotti2022epilepsyinindividualsa pages 26-31)

4.5 Curation table: identifiers and major genetic causes

Entity (disease/gene) Identifier type Identifier Notes (inheritance/phenotype) Key citation IDs
Periventricular nodular heterotopia (PVNH) / periventricular heterotopia / PNH / subependymal heterotopia Disease OMIM 300049 Neuronal migration disorder with gray-matter nodules lining the lateral ventricles; terms PVNH and PNH are used interchangeably in the literature. Classical form is often bilateral/symmetric and strongly associated with epilepsy. (parrini2004mosaicmutationsof pages 1-2, fernandes2024periventricularnodularheterotopias pages 1-2, lange201547patientswith pages 1-2, paliotti2022epilepsyinindividualsa pages 8-13)
FLNA (historically FLN1) Gene OMIM *300017 Most common cause of classical bilateral/symmetric PVNH; X-linked dominant; female predominance with high prenatal/perinatal lethality in hemizygous males; extracerebral features can include cardiovascular, pulmonary, gastrointestinal, connective-tissue, and hematologic abnormalities. (parrini2004mosaicmutationsof pages 1-2, lange201547patientswith pages 1-2, lapointe2014germlinemosaicismin pages 1-3, cannaerts2018flnamutationsin pages 1-3)
ARF1 Gene identifier not available in gathered evidence De novo variants identified in 17 unrelated individuals; autosomal-dominant ARF1-related neurodevelopmental disorder with severe ID, microcephaly, seizures, and PVNH due to impaired neuronal migration. (agathe2023arf1relateddisorderphenotypic pages 1-2, agathe2023arf1relateddisorderphenotypic pages 1-1)
TAOK1 Gene identifier not available in gathered evidence Heterozygous truncating TAOK1 variant reported in a boy with PVNH; described as the first reported neuronal migration disorder in TAOK1-related neurodevelopmental disease. Usually de novo in published cases, with variable developmental delay/NDD phenotype. (cavalli2024heterozygoustruncatingvariant pages 1-3)
DCHS1 Gene identifier not available in gathered evidence Reported genetic cause of periventricular heterotopia/gray matter heterotopia; patient-derived hNPCs show migration defects linked to altered autophagy and paxillin accumulation; wild-type DCHS1 can rescue morphology in model systems. (bressan2023metforminrescuesmigratory pages 1-2, bressan2023metforminrescuesmigratory pages 6-7, bressan2023metforminrescuesmigratory pages 9-10)
FAT4 Gene identifier not available in gathered evidence Reported genetic cause of periventricular heterotopia/gray matter heterotopia; DCHS1/FAT4-mutant hNPCs show impaired migration and altered autophagy; metformin promoted migration rescue experimentally. (bressan2023metforminrescuesmigratory pages 1-2, bressan2023metforminrescuesmigratory pages 6-7, bressan2023metforminrescuesmigratory pages 9-10)
ARFGEF2 Gene identifier OMIM 608097 Mentioned as a non-FLNA PVNH gene; associated in evidence with autosomal-recessive forms and with microcephaly plus PVNH/neuronal migration disorder; mechanistically linked to vesicle trafficking. (gerlevik2022computationalanalysisof pages 1-2, agathe2023arf1relateddisorderphenotypic pages 1-2, lange201547patientswith pages 1-2)
NEDD4L Gene identifier not available in gathered evidence Mentioned among PVNH genes; evidence links NEDD4L-related disease to AKT-mTOR deregulation and migration-related pathology in broader PVNH literature summarized in cohort/thesis evidence. (paliotti2022epilepsyinindividuals pages 44-47, paliotti2022epilepsyinindividualsa pages 17-22)
MAP1B Gene identifier not available in gathered evidence Mentioned among implicated PVNH genes; private de novo/inherited variants reported in PVNH and included in disease heterogeneity summaries. (paliotti2022epilepsyinindividualsa pages 17-22)
TMTC3 Gene identifier not available in gathered evidence Recessive association with PVNH, intellectual disability, and epilepsy; three of four affected siblings had PVNH in the cited study. (gerlevik2022computationalanalysisof pages 1-2)

Table: This table summarizes core disease terminology and the main genes implicated in periventricular nodular heterotopia/periventricular heterotopia based on the gathered evidence. It highlights which identifiers were directly supported in-context and which entries currently lack explicit identifier data in the available evidence.

5. Environmental information

No specific toxin, lifestyle, or infectious contributors were identified in the retrieved evidence corpus; PVNH is treated primarily as a genetic neurodevelopmental condition. (parrini2004mosaicmutationsof pages 1-2)

6. Mechanism / pathophysiology

6.1 Unifying biological concept

The core mechanistic concept is disruption of neuronal migration during corticogenesis, producing ectopic gray-matter nodules adjacent to the ventricles. (parrini2004mosaicmutationsof pages 1-2, paliotti2022epilepsyinindividualsa pages 8-13)

6.2 Mechanistic axes with causal chains (examples)

  1. FLNA LoF → cytoskeletal dysregulation → impaired migration → PVNH nodules → epilepsy and multisystem disease

  2. FLNA is an actin-binding/cytoskeletal protein implicated in cell migration; LoF variants cause failure of neurons to migrate, leaving nodules at the ventricular surface. (rijckmans2024counselingindividualswith pages 1-3, parrini2004mosaicmutationsof pages 1-2)

  3. ARF1 de novo variants → altered small-GTPase/vesicle trafficking (trans-Golgi) → impaired neuronal migration → PVNH within a syndromic NDD

  4. ARF1 “acts as a molecular switch” and ARF1-GTP “promotes trans-Golgi and the fission step of the vesicle formation,” linking vesicle trafficking to migration disorders. (agathe2023arf1relateddisorderphenotypic pages 1-2)

  5. DCHS1/FAT4 mutations → impaired autophagic flux and focal adhesion recycling → hNPC migration deficits → heterotopia phenotypes

  6. The migration defect is linked to altered autophagy with paxillin accumulation; “Metformin, an FDA-approved drug, was used to trigger autophagy… and restored the migration of hNPCs derived from PH patients.” (bressan2023metforminrescuesmigratory pages 11-12, bressan2023metforminrescuesmigratory pages 1-2)

6.3 Suggested GO biological process and CL cell type terms

A curation-ready mapping of implicated processes and cell types is provided below.

Gene/axis Mechanistic theme Upstream defect Downstream cellular phenotype Evidence system (human/organoid/hNPC xenograft) Therapeutic implication Suggested GO biological process terms Suggested CL cell types
FLNA Actin cytoskeleton organization and neuronal migration Loss-of-function variants in X-linked FLNA disrupt filamin A, an actin-binding cytoskeletal scaffold required for cell motility/migration during corticogenesis Failure of subsets of neurons to migrate from the ventricular zone to cortex, producing bilateral/symmetric periventricular nodules; epilepsy and multisystem manifestations in many affected individuals (parrini2004mosaicmutationsof pages 1-2, lange201547patientswith pages 1-2, paliotti2022epilepsyinindividualsa pages 17-22) Human clinical/genetic cohorts and case series (parrini2004mosaicmutationsof pages 1-2, lange201547patientswith pages 1-2, paliotti2022epilepsyinindividualsa pages 17-22) No established pathway-targeted therapy; strong rationale for genetic diagnosis plus surveillance/management rather than mechanism-based drug treatment at present (rijckmans2024counselingindividualswith pages 1-3, lange201547patientswith pages 1-2) GO:0007010 cytoskeleton organization; GO:0007411 axon guidance; GO:0001764 neuron migration; GO:0030036 actin cytoskeleton organization CL:0000540 neuron; CL:0011115 neural progenitor cell; CL:0011116 radial glial cell
ARF1 / ARFGEF2 Vesicle trafficking and trans-Golgi network regulation in neuronal migration De novo ARF1 variants alter a small GTPase molecular switch; ARFGEF2 dysfunction perturbs guanine-exchange control of ARF signaling and vesicle formation/trafficking from the trans-Golgi (agathe2023arf1relateddisorderphenotypic pages 1-2, agathe2023arf1relateddisorderphenotypic pages 1-1, gerlevik2022computationalanalysisof pages 1-2) Impaired neuronal migration with PVNH, microcephaly, seizures, and neurodevelopmental disorder; broader migration disorder pattern on MRI (agathe2023arf1relateddisorderphenotypic pages 1-2, agathe2023arf1relateddisorderphenotypic pages 1-1) Human cohort/genetic study with functional validation for ARF1; human genetic association summaries for ARFGEF2 (agathe2023arf1relateddisorderphenotypic pages 1-2, agathe2023arf1relateddisorderphenotypic pages 1-1, gerlevik2022computationalanalysisof pages 1-2) Primarily diagnostic/genetic-counseling relevance currently; no validated targeted therapy identified in available evidence GO:0016192 vesicle-mediated transport; GO:0006891 intra-Golgi vesicle-mediated transport; GO:0006886 intracellular protein transport; GO:0001764 neuron migration CL:0011115 neural progenitor cell; CL:0000540 neuron
DCHS1 / FAT4 Autophagy-dependent migration control; AMPK-autophagy-paxillin/focal adhesion axis DCHS1 or FAT4 mutations impair autophagic flux, including defective autophagosome-lysosome fusion and accumulation of paxillin/focal adhesion components; pathway intersects with AMPK and cellular energy sensing (bressan2023metforminrescuesmigratory pages 1-2, bressan2023metforminrescuesmigratory pages 6-7, bressan2023metforminrescuesmigratory pages 9-10, bressan2023metforminrescuesmigratory pages 7-9) Altered migratory dynamics of human neural progenitor cells, shorter migratory phases, abnormal actin/Golgi organization, exaggerated neuronal/network hyperactivity in derived models, and heterotopia-like phenotypes (bressan2023metforminrescuesmigratory pages 1-2, bressan2023metforminrescuesmigratory pages 11-12, bressan2023metforminrescuesmigratory pages 9-10) Human patient-derived hNPCs, cortical organoids, xenografts into mouse brain, and organoid electrophysiology/proteogenomic analyses (bressan2023metforminrescuesmigratory pages 1-2, bressan2023metforminrescuesmigratory pages 6-7, bressan2023metforminrescuesmigratory pages 9-10) Metformin enhanced AMPK-dependent autophagy and rescued migration defects experimentally; autophagy/mTOR modulation is a candidate translational strategy in selected PH forms (bressan2023metforminrescuesmigratory pages 1-2, bressan2023metforminrescuesmigratory pages 10-11, bressan2023metforminrescuesmigratory pages 11-12) GO:0006914 autophagy; GO:1905037 autophagosome organization; GO:0030335 positive regulation of cell migration; GO:0001764 neuron migration; GO:0005925 focal adhesion CL:0011115 neural progenitor cell; CL:0000540 neuron
TAOK1 Microtubule/cytoskeleton regulation and stress-activated MAPK signaling during cortical maturation Heterozygous truncating TAOK1 variants disrupt a MAP3K family kinase important for neuronal maturation, cortical differentiation, microtubule stability, cytoskeletal dynamics, and stress-activated MAPK pathway signaling (cavalli2024heterozygoustruncatingvariant pages 1-3) Neurodevelopmental disorder with PVNH in the reported case, supporting a neuronal migration defect linked to impaired cortical development/cytoskeletal regulation (cavalli2024heterozygoustruncatingvariant pages 1-3) Human case report plus literature review; mechanistic support largely inferred from prior experimental biology summarized in the report (cavalli2024heterozygoustruncatingvariant pages 1-3) No validated targeted therapy in available evidence; principal value is expanding diagnostic panels and mechanistic stratification GO:0000226 microtubule cytoskeleton organization; GO:0001764 neuron migration; GO:0007254 JNK cascade; GO:0030154 cell differentiation CL:0011115 neural progenitor cell; CL:0000540 neuron
NEDD4L / AKT-mTOR axis Ubiquitin signaling with AKT-mTOR deregulation affecting cortical development and migration Pathogenic NEDD4L variants are summarized as causing AKT-mTOR deregulation in PVNH-related disease references (paliotti2022epilepsyinindividuals pages 44-47, bressan2023metforminrescuesmigratory pages 10-11) Abnormal neuronal migration/cortical development contributing to PVNH phenotypes; specific downstream cellular details are less developed in the available evidence than for DCHS1/FAT4 (paliotti2022epilepsyinindividuals pages 44-47, bressan2023metforminrescuesmigratory pages 10-11) Human genetic/clinical literature summaries; mechanistic mention in review/thesis evidence rather than a dedicated primary mechanistic paper in available context (paliotti2022epilepsyinindividuals pages 44-47, bressan2023metforminrescuesmigratory pages 10-11) Rapamycin-like/autophagy-activating approaches are noted as partially rescuing migration in related cited contexts, supporting mTOR-pathway modulation as a hypothesis-generating avenue (bressan2023metforminrescuesmigratory pages 10-11) GO:0010506 regulation of autophagy; GO:0032008 positive regulation of TOR signaling; GO:0001764 neuron migration; GO:0046777 protein autoubiquitination CL:0011115 neural progenitor cell; CL:0000540 neuron

Table: This table summarizes the main mechanistic axes currently implicated in periventricular nodular heterotopia/periventricular heterotopia, linking genes to cellular defects, evidence systems, and translational implications. It is useful for mapping disease biology into structured pathway, cell type, and therapeutic hypothesis annotations.

7. Anatomical structures affected

7.1 Primary organs/systems

  • Central nervous system (brain) is primary, especially periventricular region surrounding the lateral ventricles. (paliotti2022epilepsyinindividualsa pages 8-13)

7.2 Specific anatomical localization (example UBERON suggestions)

  • Lateral ventricle / ventricular zone region (UBERON suggestion: lateral ventricle of brain)
  • Periventricular region / subependymal zone

(UBERON IDs are not present in the retrieved evidence corpus; terms above are suggested for ontology mapping based on described anatomy.) (paliotti2022epilepsyinindividualsa pages 8-13)

7.3 Extra-CNS involvement (FLNA deficiency)

  • Cardiovascular system involvement (valvular disease, aortic root involvement, congenital lesions) is common in FLNA LoF cohorts, motivating surveillance. (rijckmans2024counselingindividualswith pages 6-8, rijckmans2024counselingindividualswith pages 5-6)

8. Temporal development

  • Onset: PVNH is congenital (developmental), but clinical presentation often occurs later with seizure onset in childhood/adolescence; mean seizure onset 7.9 years in one cohort and median 17 years in a FLNA LoF cohort. (paliotti2022epilepsyinindividualsa pages 26-31, rijckmans2024counselingindividualswith pages 5-6)
  • Course: Variable—ranging from self-limited epilepsy (10% in one cohort) to drug-resistant epilepsy (23% overall; enriched in multiple bilateral PVNH). (paliotti2022epilepsyinindividualsa pages 26-31)

9. Inheritance and population

9.1 Inheritance patterns

  • X-linked dominant: FLNA-associated PVNH/FLNA deficiency, with reduced male viability and frequent female predominance. (lange201547patientswith pages 1-2, cannaerts2018flnamutationsin pages 1-3)
  • Autosomal dominant (de novo): ARF1-related disorder (17 unrelated individuals with de novo variants). (agathe2023arf1relateddisorderphenotypic pages 1-1)

9.2 Penetrance/expressivity and mosaicism

  • Incomplete penetrance for seizures is supported by seizure-free FLNA variant carriers (e.g., 10 carriers seizure-free at median age 19.7 years in a 47-person cohort). (lange201547patientswith pages 1-2)
  • Mosaicism and germline mosaicism are documented and relevant for recurrence risk and male survival. (lapointe2014germlinemosaicismin pages 1-3, lange201547patientswith pages 4-6)

9.3 Epidemiology and prevalence/incidence

No population-level prevalence or incidence rates were available in the retrieved evidence corpus. (rijckmans2024counselingindividualswith pages 3-5)

10. Diagnostics

10.1 Imaging

MRI is the central diagnostic tool. In a 2024 case report, the authors state: “Head magnetic resonance imaging (MRI) is the most sensitive neuroimaging method,” and describe “bilateral subependymal nodular irregularities lining the lateral ventricles, with similar signal evolution to grey matter.” (fernandes2024periventricularnodularheterotopias pages 1-2)

MRI pattern stratification is clinically useful. One cohort classified PVNH into four patterns (anterior predominant bilateral symmetric; inferior; bilateral asymmetric; unilateral focal) and reported FLNA-positive cases were predominantly anterior bilateral symmetric (8/9). (lu2022theclinicaland pages 1-8)

An MRI figure demonstrating bilateral periventricular nodules (arrows) is available from the retrieved case report. (fernandes2024periventricularnodularheterotopias media ff0bd3e1)

10.2 EEG

EEG abnormalities are frequent: in a 100-person cohort, EEG was abnormal in 95% (92/99), with focal, multifocal, and generalized patterns. (paliotti2022epilepsyinindividualsa pages 26-31)

10.3 Genetic testing approaches

Real-world diagnostic testing in PVNH includes sequencing plus CNV detection: - In a 100-person cohort: single-gene sequencing (n=17), clinical panels (n=19), WES (n=6), and CMA (n=20) were used; eight pathogenic/likely pathogenic single-gene variants and CNVs (including pathogenic CNVs) were identified. (paliotti2022epilepsyinindividualsa pages 26-31) - In FLNA-focused cohorts: FLNA testing included Sanger sequencing and MLPA, and/or NGS panels. (lange201547patientswith pages 1-2, rijckmans2025"phenotypicandgenotypic pages 6-10)

10.4 Differential diagnosis

The retrieved evidence supports a radiologic distinction between PVNH-only vs PVNH-plus (PVNH with additional malformations such as corpus callosum abnormalities, polymicrogyria, ventriculomegaly, hippocampal abnormalities). (paliotti2022epilepsyinindividualsa pages 26-31)

A comprehensive differential diagnosis list (e.g., tubulinopathies, other MCDs) was not extractable from the retrieved corpus in this run.

11. Outcome / prognosis

  • Epilepsy outcomes: In the 100-person cohort: 10% self-limited, 35% pharmacoresponsive (mean seizure-free 4.5 years), 55% uncontrolled at interview; 23% drug-resistant. (paliotti2022epilepsyinindividualsa pages 26-31)
  • Prognostic imaging correlates: Drug resistance enriched in multiple bilateral PVNH (39% of that subgroup). (paliotti2022epilepsyinindividualsa pages 26-31)
  • Neurodevelopment: Many FLNA-PVNH individuals have normal cognition or mild impairment; one FLNA cohort emphasized generally reassuring educational outcomes (22/24 attending regular school). (lange201547patientswith pages 1-2)
  • Potential mortality risks in FLNA deficiency: Cardiovascular disease can be progressive; fatal aortic rupture has been reported at smaller-than-expected diameters, supporting routine cardiological follow-up. (rijckmans2024counselingindividualswith pages 6-8, rijckmans2025"phenotypicandgenotypic pages 10-14)

12. Treatment

12.1 Pharmacotherapy (symptomatic)

In a 100-person PVNH cohort: - Clobazam was reported with high efficacy (PVNH-only 76% [13/17]; PVNH-plus 64% [16/25]). (paliotti2022epilepsyinindividualsa pages 26-31) - Levetiracetam “provided seizure freedom in 14 cases,” often as monotherapy in responders. (paliotti2022epilepsyinindividualsa pages 26-31)

MAXO suggestions: antiseizure medication therapy (MAXO term suggestion: anticonvulsant therapy), epilepsy management.

12.2 Device/dietary therapies

VNS and ketogenic diet were tried in 14 individuals; 71% reported no benefit and none achieved seizure freedom. (paliotti2022epilepsyinindividualsa pages 26-31)

MAXO suggestions: vagus nerve stimulation (device-based neuromodulation), ketogenic diet therapy.

12.3 Surgical and interventional epilepsy treatment

  • In a 100-person cohort, 12 underwent epilepsy surgery; outcomes were mixed: 2 seizure-free (on ASMs), 7 improved, 3 no clear benefit; radiofrequency thermocoagulation of nodules was performed in 4. (paliotti2022epilepsyinindividuals pages 26-31)
  • SEEG-guided thermocoagulation is a key real-world implementation; one report cites an overall efficacy of ~65% for SEEG-guided THC in PVNH, and in FLNA-positive PVNH cases outcomes varied (Engel I–II in 2/4, Engel III in 1/4, Engel IV in 1/4). (clerck2025stereoelectroencephalographicthermocoagulationin pages 1-2)

MAXO suggestions: stereoelectroencephalography, radiofrequency ablation/thermocoagulation, epilepsy surgery.

12.4 Experimental / mechanism-based approaches (preclinical)

A major 2023 mechanistic study in DCHS1/FAT4-related periventricular heterotopia demonstrated autophagy-linked migration defects in patient-derived hNPCs and showed that metformin promoted migration rescue, supporting an AMPK–autophagy therapeutic hypothesis in select genetic subtypes (preclinical). (bressan2023metforminrescuesmigratory pages 1-2, bressan2023metforminrescuesmigratory pages 11-12)

13. Prevention

No established primary prevention exists for genetically determined PVNH in the retrieved evidence. Preventive approaches are primarily genetic counseling and surveillance for complications (e.g., cardiology in FLNA deficiency). (rijckmans2024counselingindividualswith pages 6-8, lapointe2014germlinemosaicismin pages 1-3)

14. Other species / natural disease

No naturally occurring veterinary PVNH analogs were identified in the retrieved evidence.

15. Model organisms and experimental systems

PVNH/heterotopia modeling spans invertebrate, rodent, and human stem-cell systems: - Drosophila (TMTC3 ortholog): neuron-specific knockdown increased susceptibility to induced seizures; rescue by neuron-specific human TMTC3 expression supports conserved seizure biology. (farhan2017identificationofa pages 1-2) - Human iPSC/hNPC and cortical organoids: patient-derived hNPCs and organoids for DCHS1/FAT4 periventricular heterotopia; xenografting hNPCs into mouse brain enabled in vivo migration assays and metformin rescue experiments. (bressan2023metforminrescuesmigratory pages 1-2) - Rodent FLNA models: mouse FLNA loss-of-function models do not consistently reproduce the human neuronal migration defect/PVNH phenotype, indicating interspecies limitations; rat approaches may be more comparable but resource-intensive. (donada2018physiopathologicalmechanismsof pages 166-168, benadero2019geneticalterationsin pages 105-109)

Recent developments (2023–2024 highlights)

  1. ARF1-related disorder (2023, Journal of Medical Genetics): expanded from a handful of cases to a 17-individual cohort with de novo ARF1 variants and recurrent PVNH, seizures, microcephaly, and ID, with mechanistic linkage to vesicle formation at the trans-Golgi. URL: https://doi.org/10.1136/jmg-2022-108803 (Apr 2023). (agathe2023arf1relateddisorderphenotypic pages 1-1, agathe2023arf1relateddisorderphenotypic pages 1-2)
  2. Metformin/autophagy rescue in DCHS1/FAT4 periventricular heterotopia (2023, EMBO Molecular Medicine): patient-derived hNPC migration deficits linked to altered autophagy and paxillin accumulation; metformin increased autophagic flux and restored migration in preclinical models. URL: https://doi.org/10.15252/emmm.202216908 (Aug 2023). (bressan2023metforminrescuesmigratory pages 1-2, bressan2023metforminrescuesmigratory pages 11-12)
  3. TAOK1 association with PVNH (2024, BMC Medical Genomics): first report of a TAOK1-related NDD case with PVNH, supporting TAOK1’s role in neuronal migration/cytoskeleton biology. URL: https://doi.org/10.1186/s12920-024-01840-8 (Mar 2024). (cavalli2024heterozygoustruncatingvariant pages 1-3)
  4. FLNA LoF surveillance emphasis (2024 preprint): cohort data underscore frequent epilepsy and cardiovascular involvement and highlight that “guidelines are lacking,” motivating multidisciplinary follow-up and cardiologic screening. URL: https://doi.org/10.21203/rs.3.rs-4546691/v1 (Oct 2024). (rijckmans2024counselingindividualswith pages 1-3, rijckmans2024counselingindividualswith pages 6-8)

Real-world implementations / research infrastructure

  • EPGP (NCT00552045): A completed, large observational epilepsy genetics project (enrollment 4,150) that explicitly includes “Periventricular Heterotopias” among conditions studied; collected whole-blood DNA and required parent participation for MCD cases. https://clinicaltrials.gov/study/NCT00552045 (first posted 2007). (NCT00552045 chunk 1)
  • RID functional testing for VUS (NCT05696912): Diagnostic-focused study to reclassify VUS via RNA-seq/minigene/luciferase functional assays; includes PVNH among conditions. https://clinicaltrials.gov/study/NCT05696912 (first posted 2023). (NCT05696912 chunk 1)

Notes on citation requirements (PMIDs)

Where possible, this report cites primary literature and includes DOIs/URLs with publication months/years. However, PMID values were not present in the retrieved text extracts for this run, so PMIDs cannot be reliably provided without external database lookup. All major claims are nevertheless tied to the provided evidence excerpts via the in-run citation IDs.

References

  1. (agathe2023arf1relateddisorderphenotypic pages 1-2): Jean-Madeleine de Sainte Agathe, Ben Pode-Shakked, Sophie Naudion, Vincent Michaud, Benoit Arveiler, Patricia Fergelot, Jean Delmas, Boris Keren, Céline Poirsier, Fowzan S Alkuraya, Brahim Tabarki, Eric Bend, Kellie Davis, Martina Bebin, Michelle L Thompson, Emily M Bryant, Matias Wagner, Iris Hannibal, Jerica Lenberg, Martin Krenn, Kristen M Wigby, Jennifer R Friedman, Maria Iascone, Anna Cereda, Térence Miao, Eric LeGuern, Emanuela Argilli, Elliott Sherr, Oana Caluseriu, Timothy Tidwell, Pinar Bayrak-Toydemir, Caroline Hagedorn, Melanie Brugger, Katharina Vill, Francois-Dominique Morneau-Jacob, Wendy Chung, Kathryn N Weaver, Joshua W Owens, Ammar Husami, Bimal P Chaudhari, Brandon S Stone, Katie Burns, Rachel Li, Iris M de Lange, Margaux Biehler, Emmanuelle Ginglinger, Bénédicte Gérard, Rolf W Stottmann, and Aurélien Trimouille. Arf1-related disorder: phenotypic and molecular spectrum. Journal of Medical Genetics, 60:999-1005, Apr 2023. URL: https://doi.org/10.1136/jmg-2022-108803, doi:10.1136/jmg-2022-108803. This article has 13 citations and is from a domain leading peer-reviewed journal.

  2. (cavalli2024heterozygoustruncatingvariant pages 1-3): Anna Cavalli, Stefano Giuseppe Caraffi, Susanna Rizzi, Gabriele Trimarchi, Manuela Napoli, Daniele Frattini, Carlotta Spagnoli, Livia Garavelli, and Carlo Fusco. Heterozygous truncating variant of taok1 in a boy with periventricular nodular heterotopia: a case report and literature review of taok1-related neurodevelopmental disorders. BMC Medical Genomics, Mar 2024. URL: https://doi.org/10.1186/s12920-024-01840-8, doi:10.1186/s12920-024-01840-8. This article has 4 citations and is from a peer-reviewed journal.

  3. (bressan2023metforminrescuesmigratory pages 1-2): Cedric Bressan, Marta Snapyan, Marina Snapyan, Johannes Klaus, Francesco di Matteo, Stephen P Robertson, Barbara Treutlein, Martin Parent, Silvia Cappello, and Armen Saghatelyan. Metformin rescues migratory deficits of cells derived from patients with periventricular heterotopia. EMBO Molecular Medicine, Aug 2023. URL: https://doi.org/10.15252/emmm.202216908, doi:10.15252/emmm.202216908. This article has 3 citations and is from a highest quality peer-reviewed journal.

  4. (parrini2004mosaicmutationsof pages 1-2): Elena Parrini, Davide Mei, Micheal Wright, Thomas Dorn, and Renzo Guerrini. Mosaic mutations of the fln1 gene cause a mild phenotype in patients with periventricular heterotopia. Neurogenetics, 5:191-196, Jul 2004. URL: https://doi.org/10.1007/s10048-004-0187-y, doi:10.1007/s10048-004-0187-y. This article has 52 citations and is from a peer-reviewed journal.

  5. (fernandes2024periventricularnodularheterotopias pages 1-2): Andreia Fernandes, Mafalda J Pereira, Íris Oliveira, André M Travessa, José Drago, and Carla Mendonça. Periventricular nodular heterotopias induced-seizures in an adolescent. Cureus, Dec 2024. URL: https://doi.org/10.7759/cureus.75272, doi:10.7759/cureus.75272. This article has 0 citations.

  6. (lu2022theclinicaland pages 1-8): Yan-Ting Lu, Chung-Yao Hsu, Yo-Tsen Liu, Chung-Kin Chan, Yao-Chung Chuang, Chih-Hsiang Lin, Kai-Ping Chang, Chen-Jui Ho, Ching-Ching Ng, Kheng-Seang Lim, and Meng-Han Tsai. The clinical and imaging features of flna positive and negative periventricular nodular heterotopia. Biomedical Journal, 45:542-548, Jun 2022. URL: https://doi.org/10.1016/j.bj.2021.05.003, doi:10.1016/j.bj.2021.05.003. This article has 11 citations.

  7. (gerlevik2022computationalanalysisof pages 1-2): Umut Gerlevik, Ceren Saygı, Hakan Cangül, Aslı Kutlu, Erdal Fırat Çaralan, Yasemin Topçu, Nesrin Özören, and Osman Uğur Sezerman. Computational analysis of missense filamin-a variants, including the novel p.arg484gln variant of two brothers with periventricular nodular heterotopia. PLOS ONE, 17:e0265400, May 2022. URL: https://doi.org/10.1371/journal.pone.0265400, doi:10.1371/journal.pone.0265400. This article has 2 citations and is from a peer-reviewed journal.

  8. (paliotti2022epilepsyinindividualsa pages 8-13): K Paliotti. Epilepsy in individuals with periventricular nodular heterotopia: defining the clinical phenotypic spectrum and underlying molecular causes. Unknown journal, 2022.

  9. (rijckmans2024counselingindividualswith pages 1-3): Ellen RIJCKMANS, Lars P. De Strooper, Kathelijn Keymolen, Jessica Rosenblum, Bart Loeys, Marije Meuwissen, Anna C. Jansen, and Katrien Stouffs. Counseling individuals with pathogenic loss-of-function variants in flna – learning points from a cross-sectional cohort study. Unknown journal, Oct 2024. URL: https://doi.org/10.21203/rs.3.rs-4546691/v1, doi:10.21203/rs.3.rs-4546691/v1.

  10. (lange201547patientswith pages 1-2): Max Lange, Burkhard Kasper, Axel Bohring, Frank Rutsch, Gerhard Kluger, Sabine Hoffjan, Stephanie Spranger, Anne Behnecke, Andreas Ferbert, Andreas Hahn, Barbara Oehl-Jaschkowitz, Luitgard Graul-Neumann, Katharina Diepold, Isolde Schreyer, Matthias K. Bernhard, Franziska Mueller, Ulrike Siebers-Renelt, Ana Beleza-Meireles, Goekhan Uyanik, Sandra Janssens, Eugen Boltshauser, Juergen Winkler, Gerhard Schuierer, and Ute Hehr. 47 patients with flna associated periventricular nodular heterotopia. Orphanet Journal of Rare Diseases, Oct 2015. URL: https://doi.org/10.1186/s13023-015-0331-9, doi:10.1186/s13023-015-0331-9. This article has 116 citations and is from a peer-reviewed journal.

  11. (paliotti2022epilepsyinindividualsa pages 26-31): K Paliotti. Epilepsy in individuals with periventricular nodular heterotopia: defining the clinical phenotypic spectrum and underlying molecular causes. Unknown journal, 2022.

  12. (bressan2023metforminrescuesmigratory pages 9-10): Cedric Bressan, Marta Snapyan, Marina Snapyan, Johannes Klaus, Francesco di Matteo, Stephen P Robertson, Barbara Treutlein, Martin Parent, Silvia Cappello, and Armen Saghatelyan. Metformin rescues migratory deficits of cells derived from patients with periventricular heterotopia. EMBO Molecular Medicine, Aug 2023. URL: https://doi.org/10.15252/emmm.202216908, doi:10.15252/emmm.202216908. This article has 3 citations and is from a highest quality peer-reviewed journal.

  13. (NCT00552045 chunk 1): Epilepsy Phenome/Genome Project. University of California, San Francisco. 2007. ClinicalTrials.gov Identifier: NCT00552045

  14. (NCT05696912 chunk 1): Functional Tests to Resolve Unsolved Rare Diseases. Rares.. University Hospital, Bordeaux. 2023. ClinicalTrials.gov Identifier: NCT05696912

  15. (cannaerts2018flnamutationsin pages 1-3): Elyssa Cannaerts, Anju Shukla, Mensuda Hasanhodzic, Maaike Alaerts, Dorien Schepers, Lut Van Laer, Katta M. Girisha, Iva Hojsak, Bart Loeys, and Aline Verstraeten. Flna mutations in surviving males presenting with connective tissue findings: two new case reports and review of the literature. BMC Medical Genetics, Sep 2018. URL: https://doi.org/10.1186/s12881-018-0655-0, doi:10.1186/s12881-018-0655-0. This article has 38 citations and is from a peer-reviewed journal.

  16. (lange201547patientswith pages 4-6): Max Lange, Burkhard Kasper, Axel Bohring, Frank Rutsch, Gerhard Kluger, Sabine Hoffjan, Stephanie Spranger, Anne Behnecke, Andreas Ferbert, Andreas Hahn, Barbara Oehl-Jaschkowitz, Luitgard Graul-Neumann, Katharina Diepold, Isolde Schreyer, Matthias K. Bernhard, Franziska Mueller, Ulrike Siebers-Renelt, Ana Beleza-Meireles, Goekhan Uyanik, Sandra Janssens, Eugen Boltshauser, Juergen Winkler, Gerhard Schuierer, and Ute Hehr. 47 patients with flna associated periventricular nodular heterotopia. Orphanet Journal of Rare Diseases, Oct 2015. URL: https://doi.org/10.1186/s13023-015-0331-9, doi:10.1186/s13023-015-0331-9. This article has 116 citations and is from a peer-reviewed journal.

  17. (agathe2023arf1relateddisorderphenotypic pages 1-1): Jean-Madeleine de Sainte Agathe, Ben Pode-Shakked, Sophie Naudion, Vincent Michaud, Benoit Arveiler, Patricia Fergelot, Jean Delmas, Boris Keren, Céline Poirsier, Fowzan S Alkuraya, Brahim Tabarki, Eric Bend, Kellie Davis, Martina Bebin, Michelle L Thompson, Emily M Bryant, Matias Wagner, Iris Hannibal, Jerica Lenberg, Martin Krenn, Kristen M Wigby, Jennifer R Friedman, Maria Iascone, Anna Cereda, Térence Miao, Eric LeGuern, Emanuela Argilli, Elliott Sherr, Oana Caluseriu, Timothy Tidwell, Pinar Bayrak-Toydemir, Caroline Hagedorn, Melanie Brugger, Katharina Vill, Francois-Dominique Morneau-Jacob, Wendy Chung, Kathryn N Weaver, Joshua W Owens, Ammar Husami, Bimal P Chaudhari, Brandon S Stone, Katie Burns, Rachel Li, Iris M de Lange, Margaux Biehler, Emmanuelle Ginglinger, Bénédicte Gérard, Rolf W Stottmann, and Aurélien Trimouille. Arf1-related disorder: phenotypic and molecular spectrum. Journal of Medical Genetics, 60:999-1005, Apr 2023. URL: https://doi.org/10.1136/jmg-2022-108803, doi:10.1136/jmg-2022-108803. This article has 13 citations and is from a domain leading peer-reviewed journal.

  18. (paliotti2022epilepsyinindividuals pages 17-22): K Paliotti. Epilepsy in individuals with periventricular nodular heterotopia: defining the clinical phenotypic spectrum and underlying molecular causes. Unknown journal, 2022.

  19. (paliotti2022epilepsyinindividualsa pages 17-22): K Paliotti. Epilepsy in individuals with periventricular nodular heterotopia: defining the clinical phenotypic spectrum and underlying molecular causes. Unknown journal, 2022.

  20. (rijckmans2024counselingindividualswith pages 5-6): Ellen RIJCKMANS, Lars P. De Strooper, Kathelijn Keymolen, Jessica Rosenblum, Bart Loeys, Marije Meuwissen, Anna C. Jansen, and Katrien Stouffs. Counseling individuals with pathogenic loss-of-function variants in flna – learning points from a cross-sectional cohort study. Unknown journal, Oct 2024. URL: https://doi.org/10.21203/rs.3.rs-4546691/v1, doi:10.21203/rs.3.rs-4546691/v1.

  21. (rijckmans2024counselingindividualswith pages 6-8): Ellen RIJCKMANS, Lars P. De Strooper, Kathelijn Keymolen, Jessica Rosenblum, Bart Loeys, Marije Meuwissen, Anna C. Jansen, and Katrien Stouffs. Counseling individuals with pathogenic loss-of-function variants in flna – learning points from a cross-sectional cohort study. Unknown journal, Oct 2024. URL: https://doi.org/10.21203/rs.3.rs-4546691/v1, doi:10.21203/rs.3.rs-4546691/v1.

  22. (rijckmans2025"phenotypicandgenotypic pages 1-6): Ellen Rijckmans, Lars De Strooper, K. Keymolen, Jessica Rosenblum, B. Loeys, M. Meuwissen, Anna C. Jansen, and K. Stouffs. "phenotypic and genotypic insights, counseling strategies, and follow-up in 24 individuals with filamin a deficiency: findings from a retrospective cohort study". Acta neurologica Belgica, Aug 2025. URL: https://doi.org/10.1007/s13760-025-02858-0, doi:10.1007/s13760-025-02858-0. This article has 0 citations and is from a peer-reviewed journal.

  23. (rijckmans2025"phenotypicandgenotypic pages 6-10): Ellen Rijckmans, Lars De Strooper, K. Keymolen, Jessica Rosenblum, B. Loeys, M. Meuwissen, Anna C. Jansen, and K. Stouffs. "phenotypic and genotypic insights, counseling strategies, and follow-up in 24 individuals with filamin a deficiency: findings from a retrospective cohort study". Acta neurologica Belgica, Aug 2025. URL: https://doi.org/10.1007/s13760-025-02858-0, doi:10.1007/s13760-025-02858-0. This article has 0 citations and is from a peer-reviewed journal.

  24. (rijckmans2025"phenotypicandgenotypic pages 10-14): Ellen Rijckmans, Lars De Strooper, K. Keymolen, Jessica Rosenblum, B. Loeys, M. Meuwissen, Anna C. Jansen, and K. Stouffs. "phenotypic and genotypic insights, counseling strategies, and follow-up in 24 individuals with filamin a deficiency: findings from a retrospective cohort study". Acta neurologica Belgica, Aug 2025. URL: https://doi.org/10.1007/s13760-025-02858-0, doi:10.1007/s13760-025-02858-0. This article has 0 citations and is from a peer-reviewed journal.

  25. (lapointe2014germlinemosaicismin pages 1-3): Monique M LaPointe, Elizabeth L Spriggs, and Aizeddin A Mhanni. Germline mosaicism in x-linked periventricular nodular heterotopia. BMC Neurology, 14:125-125, Jun 2014. URL: https://doi.org/10.1186/1471-2377-14-125, doi:10.1186/1471-2377-14-125. This article has 11 citations and is from a peer-reviewed journal.

  26. (bressan2023metforminrescuesmigratory pages 6-7): Cedric Bressan, Marta Snapyan, Marina Snapyan, Johannes Klaus, Francesco di Matteo, Stephen P Robertson, Barbara Treutlein, Martin Parent, Silvia Cappello, and Armen Saghatelyan. Metformin rescues migratory deficits of cells derived from patients with periventricular heterotopia. EMBO Molecular Medicine, Aug 2023. URL: https://doi.org/10.15252/emmm.202216908, doi:10.15252/emmm.202216908. This article has 3 citations and is from a highest quality peer-reviewed journal.

  27. (paliotti2022epilepsyinindividuals pages 44-47): K Paliotti. Epilepsy in individuals with periventricular nodular heterotopia: defining the clinical phenotypic spectrum and underlying molecular causes. Unknown journal, 2022.

  28. (bressan2023metforminrescuesmigratory pages 11-12): Cedric Bressan, Marta Snapyan, Marina Snapyan, Johannes Klaus, Francesco di Matteo, Stephen P Robertson, Barbara Treutlein, Martin Parent, Silvia Cappello, and Armen Saghatelyan. Metformin rescues migratory deficits of cells derived from patients with periventricular heterotopia. EMBO Molecular Medicine, Aug 2023. URL: https://doi.org/10.15252/emmm.202216908, doi:10.15252/emmm.202216908. This article has 3 citations and is from a highest quality peer-reviewed journal.

  29. (bressan2023metforminrescuesmigratory pages 7-9): Cedric Bressan, Marta Snapyan, Marina Snapyan, Johannes Klaus, Francesco di Matteo, Stephen P Robertson, Barbara Treutlein, Martin Parent, Silvia Cappello, and Armen Saghatelyan. Metformin rescues migratory deficits of cells derived from patients with periventricular heterotopia. EMBO Molecular Medicine, Aug 2023. URL: https://doi.org/10.15252/emmm.202216908, doi:10.15252/emmm.202216908. This article has 3 citations and is from a highest quality peer-reviewed journal.

  30. (bressan2023metforminrescuesmigratory pages 10-11): Cedric Bressan, Marta Snapyan, Marina Snapyan, Johannes Klaus, Francesco di Matteo, Stephen P Robertson, Barbara Treutlein, Martin Parent, Silvia Cappello, and Armen Saghatelyan. Metformin rescues migratory deficits of cells derived from patients with periventricular heterotopia. EMBO Molecular Medicine, Aug 2023. URL: https://doi.org/10.15252/emmm.202216908, doi:10.15252/emmm.202216908. This article has 3 citations and is from a highest quality peer-reviewed journal.

  31. (rijckmans2024counselingindividualswith pages 3-5): Ellen RIJCKMANS, Lars P. De Strooper, Kathelijn Keymolen, Jessica Rosenblum, Bart Loeys, Marije Meuwissen, Anna C. Jansen, and Katrien Stouffs. Counseling individuals with pathogenic loss-of-function variants in flna – learning points from a cross-sectional cohort study. Unknown journal, Oct 2024. URL: https://doi.org/10.21203/rs.3.rs-4546691/v1, doi:10.21203/rs.3.rs-4546691/v1.

  32. (fernandes2024periventricularnodularheterotopias media ff0bd3e1): Andreia Fernandes, Mafalda J Pereira, Íris Oliveira, André M Travessa, José Drago, and Carla Mendonça. Periventricular nodular heterotopias induced-seizures in an adolescent. Cureus, Dec 2024. URL: https://doi.org/10.7759/cureus.75272, doi:10.7759/cureus.75272. This article has 0 citations.

  33. (paliotti2022epilepsyinindividuals pages 26-31): K Paliotti. Epilepsy in individuals with periventricular nodular heterotopia: defining the clinical phenotypic spectrum and underlying molecular causes. Unknown journal, 2022.

  34. (clerck2025stereoelectroencephalographicthermocoagulationin pages 1-2): Lucie De Clerck, Veronica Pelliccia, Romain Carron, Agnès Trébuchon, Laura Tassi, Fabrice Bartolomei, and Francesca Pizzo. Stereoelectroencephalographic thermocoagulation in flna ‐positive heterotopia: is it an effective treatment? Epilepsia, 66:e29-e34, Dec 2025. URL: https://doi.org/10.1111/epi.18231, doi:10.1111/epi.18231. This article has 1 citations and is from a domain leading peer-reviewed journal.

  35. (farhan2017identificationofa pages 1-2): Sali M. K. Farhan, K. Nixon, Michelle Everest, Michelle Everest, T. Edwards, Shirley Q. Long, Dmitri Segal, Maria J Knip, H. Arts, H. Arts, R. Chakrabarti, Jian Wang, John F. Robinson, Donald Lee, S. Mirsattari, C. Rupar, V. Siu, Michael O. Poulter, Michael O. Poulter, R. Hegele, and Jamie M. Kramer. Identification of a novel synaptic protein, tmtc3, involved in periventricular nodular heterotopia with intellectual disability and epilepsy. Human Molecular Genetics, 26:4278-4289, Aug 2017. URL: https://doi.org/10.1093/hmg/ddx316, doi:10.1093/hmg/ddx316. This article has 48 citations and is from a domain leading peer-reviewed journal.

  36. (donada2018physiopathologicalmechanismsof pages 166-168): A Donada. Physiopathological mechanisms of two congenical platelet disorders: filaminopathy-a and ankrd26-related-thrombocytopenia 5thc2. Unknown journal, 2018.

  37. (benadero2019geneticalterationsin pages 105-109): C Llinares Benadero. Genetic alterations in cortical development as a cause of epileptogenic disorders. Unknown journal, 2019.